| Name | Ziresovir |
| Description | Ziresovir (RO-0529) is a respiratory syncytial virus fusion protein (RSV F) inhibitor that inhibits RSV activity and can be used in the study of syncytial virus sensing. |
| In vitro | With EC50/EC90 values (μM) of 0.003/0.005 (WT), 2.1/10.0 (D486N), and >10/>10 (D489A), Ziresovir exhibits different efficacy in Wild Type (WT) and Mutant Strains RSV, respectively[1].Inhibiting the RSV F protein-induced cell–cell fusion process, RO-0529 (100 nM; 4 d) suppresses the syncytia formation induced by the RSV F protein[1]. |
| In vivo | Ziresovir (12.5 mg/kg, 50 mg/kg; p.o.; twice daily; 4 d) reduces RSV titer in the mouse lung[1]. With a single oral dose of 10 mg/kg, Ziresovir exhibits good exposure and 32% bioavailability in male Wistar-Han rats[1]. A single oral dose of 150 mg/kg results in higher lung distribution than plasma in CD-1 mice[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 38 mg/mL (86.46 mM), Sonication and heating are recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (4.55 mM), Sonication is recommended.
|
| Keywords | Ziresovir | RSV F | RSV | RO0529 | RO 0529 | AK-0529 | AK 0529 |
| Inhibitors Related | BTA-9881 | Ribavirin | 4-Methoxycinnamaldehyde | Roflumilast | MAY0132 | Bivalirudin | Enzaplatovir | YM-53403 | Totrombopag | Presatovir | Perflubron | Amentoflavone |
| Related Compound Libraries | Bioactive Compound Library | ReFRAME Related Library | Drug Repurposing Compound Library | Anti-Viral Compound Library | Inhibitor Library | Clinical Compound Library | Bioactive Compounds Library Max | Anti-Infection Compound Library |
United States
